9/9/10 NEWS!!Medizone International Files For Additional Bio-Terrorism Countermeasures Patent Protection
Thursday 09/09/2010 8:35 AM ET - Pr Newswire
Related Companies
| Symbol |
Last |
%Chg |
| MZEI |
0.29 |
0.00% |
As of 3:54 PM ET 9/15/10
Medizone International, Inc. (OTC Bulletin Board, OTCQB: MZEI) announces it has filed an additional international patent application covering recent developments in its variant of AsepticSure(TM) designed for government use in bio-terrorism countermeasures. The application, filed under the Patent Co-operation Treaty, extends coverage to over 120 countries, including all major industrialized countries for this government variant of the AsepticSure(TM) sterilization system.
Medizone's CEO Edwin Marshall stated, "Through the development process for our AsepticSure(TM) system, we have continued to discover new applications the system appears well suited for. Each application benefits from enhancements for the specific use intended. While our prior patent filings cover the initial discoveries and system function, we believe this filing offers a significant enhancement of intellectual property protection for this specific application. This is a step toward building a patent fence around our primary patents that we believe greatly enhances the company's intellectual property protection for the government market."
Medizone International, Inc., is a research and development company engaged in developing its AsepticSure(TM) System to decontaminate and sterilize hospital surgical suites, emergency rooms, intensive care units, schools and other critical infrastructure. A government variant is being developed for bio-terrorism countermeasures.
This Press Release contains certain forward looking statements that involve substantial risks and uncertainties, including, but not limited to, the results of ongoing clinical studies, economic conditions, product and technology development, production efficiencies, product demand, competitive products, competitive environment, successful testing and government regulatory issues. Additional risks are identified in the company's filings made with the Securities and Exchange Commission.
Investor Relations: 1-972-571-1624/ web site: www.medizoneint.com E-mail: operations@medizoneint.com
SOURCE Medizone International, Inc.